The agency now says schools no longer need to conduct Covid-19 routine testing for asymptomatic or unexposed students, suggesting schools consider doing that only in response to an outbreak, a high community risk or a high-risk event at the school, like a prom or a large sports event. The CDC also lifted previous recommendations that students quarantine if exposed to someone positive for the virus and that schools limit students’ contacts by cohorting them in groups during the day.
The agency dropped its guidance that unvaccinated people or those not up to date on their vaccines quarantine after exposure and said that schools should take the same approach for students. The recommendation is consistent with new CDC guidelines that aim to loosen quarantine recommendations and overhaul how schools approach mitigation when students return, POLITICO’s Krista Mahr reports. “If you do not have Covid-19 symptoms and believe you have been exposed to Covid-19, test again 48 hours after the first negative test, then 48 hours after the second negative test, for a total of at least three tests,” the FDA said. For those with a known exposure to Covid-19, the agency recommends testing at least three times. | Mario Tama/Getty ImagesįDA: TEST AT LEAST TWICE AT HOME, EVEN IF ASYMPTOMATIC - People using at-home Covid-19 tests should conduct repeat testing following a negative result within two or three days to cut down on the risk of unknowingly spreading the virus to others, the FDA said in a new safety communication issued Thursday. The FDA has updated its guidance about Covid-19 at-home tests to include repeat testing.
Meanwhile, vaccination supply could be limited: Although the Biden administration is working with multiple companies to put more doses of Jynneos into vials before they are shipped, it could take three to six months to get them ready, POLITICO’s Erin Banco and Adam Cancryn scoop. It’s “often considered more art than science,” he added. Intradermal administration is more common among health care providers who regularly test for tuberculosis, Osterholm said. Rollout roadblocks: There’s also the practical question about vaccine distribution. “We need answers to to provide to people who are getting vaccinated so we give them full information on what this vaccine can and can’t do,” said Michael Osterholm, the director of the Center for Infectious Disease Research and Policy at the University of Minnesota. Requesting information: Chaplin’s letter echoed a similar sentiment to what other public health experts have stressed: There needs to be ongoing data collection about the vaccine’s efficacy, particularly with an alternative delivery method, as the rollout continues. “My primary worry - even if this turns out to be equally equivalent, which I think odds are it will - will people trust it enough to get the vaccine?” James Krellenstein, managing director of the advocacy group PrEP4All, told POLITICO. The study did not look at the shot’s overall efficacy, and it’s still unclear how much protection the vaccine offers under either mode of administration.Įxperts stressed that the strategy could work but fear that potential recipients may not trust the strategy. The FDA said it is basing its strategy on a 2015 study that found that intradermal administration of a smaller dose led to a comparable immune response to the traditional dose under the skin. The CDC issued guidance for intradermal administration of the vaccine to providers Thursday. health care providers about administration. 9 letter to HHS officials first obtained by The Washington Post, the company’s president and CEO Paul Chaplin wrote that “we do have some reservations … due to the very limited safety data available.”Ĭhaplin also noted that his company has received a high volume of calls from U.S. The 441,000 doses of Jynneos vaccine in the Strategic National Stockpile would be stretched to 2.2 million doses.īut on the other hand, health experts and advocates immediately expressed concerns over the limited data backing the strategy, as did executives at Bavarian Nordic, the Danish company that manufactures Jynneos. Under the new authorization, health care providers would administer one-fifth of the usual vaccine dose in between layers of the skin - a technique called intradermal administration - instead of beneath it. As of Wednesday, 10,392 cases were confirmed in 49 states, up from 8,934 the day before. On the one hand, doses have been in short supply while cases are rising at an alarming rate.
HHS TO SHARE VACCINE DOSES, BUT CONCERNS, EVEN FROM THE MAKER, ABOUND - When HHS officials on Tuesday announced they had a plan to stretch the doses of Jynneos, the only FDA-cleared monkeypox vaccine, it was met with mixed reactions.
HHS will employ a dose-sharing strategy for the monkeypox vaccine.
0 kommentar(er)
